2 Typically, carcinoid syndrome is characterized by attacks ... agents most widely used to treat metastatic neuroendocrine tumors. Our experience suggests that fluoropyrimidines and anthracyclines ...

Carcinoid syndrome and carcinoid heart disease ... flushing and upper abdominal pain was referred to the neuroendocrine tumor unit by his oncologist. He had experienced a weight loss of 10 ...

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

Carcinoid syndrome describes multiple symptoms that develop from neuroendocrine tumors. While considered rare, these tumors can develop in the gastrointestinal tract or the lungs. Carcinoid ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Carcinoid syndrome is a rare condition typically affecting people with advanced carcinoid tumors. These rare, slow-growing tumors affect hormone-releasing neuroendocrine cells. The tumors can ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Carcinoid tumors are neoplasms that arise from neuroendocrine cells throughout ... Manifestations of the carcinoid syndrome include the "classic" triad of cutaneous flushing, diarrhea, and ...

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Clinical Director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute. "It was encouraging to see that ...